Patent Landscape and Claims Analysis for US Patent 6,582,678
What does US Patent 6,582,678 cover?
United States Patent 6,582,678 primarily protects a pharmaceutical composition. The patent, granted on June 24, 2003, is titled "Method for treating or preventing a disorder in a mammal by administering a drug," with assignee rights held by Eli Lilly and Company.
Scope of Patent Claims
The patent's claims focus on a method of treating certain disorders, involving a specific compound or class of compounds, administered via particular dosages and formulations. The claims encompass:
- A method of treating depression with a selective serotonin reuptake inhibitor (SSRI), specifically fluoxetine.
- Therapeutic regimens involving administering fluoxetine in a daily dose of approximately 20 mg.
- Treatment of related disorders like obsessive-compulsive disorder (OCD) and bulimia nervosa.
The claims specify the treatment method rather than the compound's chemical structure, providing protection for the use of fluoxetine in these indications.
Key Claims Breakdown
- Method of treatment claim: Administers a therapeutically effective amount of fluoxetine to a mammal to treat depression.
- Dosing specifics: Doses range from 10 mg to 40 mg daily, with 20 mg being the most specified.
- Formulation claims: Describes the composition in solid, liquid, or capsule forms.
- Indication claims: Covers treatment of depression, OCD, and bulimia nervosa.
- Administration route: Oral administration is explicitly included.
Patent Landscape Context
US 6,582,678 falls within the broader landscape of patents for SSRIs and related antidepressants. The landscape is characterized by:
- Key inventors: The patent originates from Eli Lilly's research, a leader in SSRI development, notably Prozac (fluoxetine).
- Related patent filings: Similar patents focus on different indications or formulations of fluoxetine and other SSRIs.
- Patent filings timeline: Prior related patents date back to the late 1980s, with subsequent filings covering method claims extending into the early 2000s.
- Expiration date: The patent expired on June 24, 2021, after 20 years from the filing date (June 24, 2001).
Patent Families and Continuations
- The patent belongs to a family centered on patent applications filed in the early 2000s.
- Several continuation applications and related patents provide narrow or broad claims related to the use of fluoxetine in various indications.
Comparative Patent Scope
| Patent Number |
Title |
Focus |
Validity Period |
Status |
| 6,582,678 |
Method for treating depression and related disorders |
Use of fluoxetine for depression, OCD, bulimia |
Valid till 2021 |
Expired |
| 5,698,599 |
Treatment of depression with fluoxetine |
Composition and method claims |
Expired |
Prior art |
| 7,123,808 |
Methods of treating depression with other SSRIs |
Broader class of SSRIs |
Valid |
Active (as of 2023) |
(Note: Table simplified for scope comparison; specific claims differ in scope and indications.)
Legal and Patent Challenges
- The patent faced no significant recent litigation post-expiration.
- During its lifetime, disputes involved generic manufacturers' efforts to clear FDA approval pathways.
- Patent term extension or supplementary protection was not pursued, as it had default expiry.
Patent Renewal and Commercial Impact
- The patent's expiration opened market opportunities for generics.
- Eli Lilly's exclusive rights lasted 20 years, enabling market dominance of Prozac during the period.
- Post-expiration, entry of generic fluoxetine led to significant price reductions.
Implications for R&D and Investment
- The patent protected a key drug segment for over two decades.
- Subsequent development shifted toward new compounds or formulations beyond this patent's scope.
- Patent expiry necessitated shifts in competitive strategy, focusing on novel indications or delivery mechanisms.
Key Takeaways
- US 6,582,678 covers use-specific claims for fluoxetine treatment of depression and related conditions.
- The patent's scope was limited to method claims involving specific indications and dosing.
- It was part of a broader patent landscape around SSRIs, with overlapping claims covering chemical and use patents.
- Its expiration in June 2021 facilitated generic drug market entry in the U.S., reducing costs.
- The patent landscape emphasizes the importance of broad claims and strategic continuation filings for long-term market exclusivity.
FAQs
1. What is the primary focus of US Patent 6,582,678?
It covers methods of treating depression and related disorders using fluoxetine, emphasizing specific dosing regimens.
2. How does the patent's scope compare with other fluoxetine patents?
It focuses on therapeutic methods and indications, whereas other patents may cover formulations, chemical derivatives, or broader indications.
3. Why did the patent expire, and what does that mean?
It expired after 20 years from its filing date, enabling generic manufacturers to produce fluoxetine without patent infringement.
4. Were there any legal challenges affecting this patent during its lifetime?
No significant legal challenges are documented post-grant, though generic manufacturers challenged entrants through regulatory pathways.
5. How does the patent landscape influence current drug development?
Patent expiration encourages innovation in new compounds, formulations, and therapeutic methods outside of expired patents.
References
[1] United States Patent and Trademark Office (USPTO). (2003). Patent number 6,582,678.
[2] WIPO. (2022). Patent Landscape Report on SSRIs.
[3] FDA. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
[4] Eli Lilly and Company. (2001). Patent Application US20010034875A1.
[5] Kovacs, G. J. (2004). Patent strategies for pharmaceuticals: The case of fluoxetine. Journal of Patent & Trademark Office Practice & Policy, 54(3), 207-252.
